Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,648
Recruiting: 1,431
Ph III recruiting: 179
Growth YoY: +7.9%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,489)

clinicaltrialsPublishedShowing 101–150 of 805 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06538038	Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients	active not recruiting	—	200	PrECOG, LLC.OTHER	1	Sep 9, 2026	clinicaltrials
NCT04092283	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer	active not recruiting	Phase 3	660	National Cancer Institute (NCI)NIH